Sawai Group Holdings
4887.TTSE PRIMEPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥201.7bn | ¥189.0bn | ¥176.9bn | ¥163.7bnr | ¥193.8bn | — |
| Operating income | ¥15.9bn | ¥4.0bn | ¥18.6bn | ¥16.1bnr | −¥35.9bn | — |
| Net income (owners) | ¥10.4bn | ¥12.0bn | ¥13.7bn | ¥12.7bn | −¥28.3bn | — |
| Total assets | ¥359.9bn | ¥354.6bn | ¥382.0bn | ¥364.2bn | ¥349.5bn | — |
| Net assets / equity | ¥178.6bn | ¥173.9bn | ¥218.0bn | ¥212.7bn | ¥200.1bn | ¥240.8bn |
| Operating cash flow | ¥7.4bn | ¥27.9bn | ¥23.1bn | ¥13.0bn | ¥34.3bn | — |
| EPS (basic) | ¥90.39 | ¥96.54 | ¥104.22r | ¥96.42r | ¥-215.18r | — |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 2
| Period | Form | Figures |
|---|---|---|
| 2025-04-01 → 2025-09-30 | Half-year | 80 figures · EDINET |
| 2024-04-01 → 2024-09-30 | Half-year | 82 figures · EDINET |
3 more reports are still being processed.
Segments · FY ended 2023-03
| Segment | External sales | Profit |
|---|---|---|
| Japan | ¥163.7bn | ¥16.1bn |
| USA | ¥36.6bn | ¥930m |
| Adjustments & eliminations | — | ¥0 |
| Total | ¥200.3bn | ¥17.0bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.